search
Back to results

MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study

Primary Purpose

Sarcoma

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
MRI scanning
Sponsored by
The Christie NHS Foundation Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Sarcoma

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Patients must have histologically confirmed diagnosis of intermediate/high grade soft tissue sarcoma (STS)
  • Patients must be suitable for treatment with preoperative radiotherapy and radical surgery
  • Standard radiological assessments (CT or MRI) may have already been performed but must be done within 4 weeks of starting radiotherapy
  • Patient must have measurable disease on CT/MRI imaging
  • ECOG performance status 0-2
  • Adequate pre-treatment haematological and biochemical parameters
  • Age greater than or equal to 18 years
  • No significant co-morbidity thereby excluding patient from having radical treatment.
  • No previous treatment for diagnosis of STS including neo-adjuvant chemotherapy
  • Women of child bearing age MUST have a negative pregnancy test prior to study entry and be using an adequate contraception method unless child bearing potential has been terminated by surgery/radical radiotherapy
  • Patients must have given written informed consent

Exclusion Criteria:

  • Patients with cardiac pacemakers, cochlear implants, intraocular foreign bodies or any other MRI incompatibility factors (e.g. recent surgery).
  • Patients with a known history of anaphylactic reaction to contrast material for MRI
  • Previous administration of gadoxetic acid or other contrast material 24hr prior to or after the MRI
  • Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial
  • Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial
  • Any other serious uncontrolled medical conditions
  • Clinical evidence of metastatic disease
  • Any pregnant or lactating woman
  • Any patient with a medical or psychiatric condition that impairs their ability to give informed consent
  • Evidence of impaired renal function, serum creatinine >1.5x upper limit of normal

Sites / Locations

  • The Christie NHS Foundation Trust

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

MRI scanning

Arm Description

patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.

Outcomes

Primary Outcome Measures

Correlate histological response of soft tissue sarcoma after pre-operative radiotherapy with pre-treatment DWI and DCE-MRI parameters.
The hypothesis is that quantitative biomarkers from DWI and DCE MRI can not only be produced with high spatial resolution in soft tissue sarcoma, but that these imaging biomarkers will correlate with histological and histochemical features of the tumour and will provide information to support the prediction of regional response to radiotherapy.

Secondary Outcome Measures

early response prediction of treatment using functional parameters of in-treatment imaging with DWI and DCE-MRI (e.g. relative change in apparent diffusion coefficient values)
accuracy of outlining treatment volumes using STIR. T1W, T2W and DWI MRI compared to standard planning CT and loco-regional control patterns
local recurrence patterns with pre-treatment functional MRI.
Within our study, these patients would have an additional three specialised MRI scans: one prior to the start of radiotherapy, one during the second week of radiotherapy while on treatment and one scan the week before the operation after the completion of radiotherapy

Full Information

First Posted
April 26, 2013
Last Updated
April 25, 2017
Sponsor
The Christie NHS Foundation Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT01956019
Brief Title
MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study
Official Title
Feasibility Study to Compare Early Response Assessment and Planning Volumes With Contrast-enhanced Computed Tomography (CT), MRI Including Diffusion Weighted MRI (DWI) and Dynamic-contrast Enhanced (DCE) MRI in Patients With Limb Sarcoma Undergoing Pre-operative Radiotherapy
Study Type
Interventional

2. Study Status

Record Verification Date
April 2017
Overall Recruitment Status
Completed
Study Start Date
February 2014 (Actual)
Primary Completion Date
January 2017 (Actual)
Study Completion Date
January 2017 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
The Christie NHS Foundation Trust

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will use diffusion weighted MRI (DWI MRI) and dynamic-contrast enhanced MRI (DCE MRI) techniques to detect changes in sarcoma tumour vasculature. The main aims of this study are to correlate histological response of soft tissue sarcoma after pre-operative radiotherapy with several pre-treatment DCE and DWI MRI parameters and to assess the impact of these on early response prediction. Detected changes may reflect the sensitivity of the tumour to radiotherapy and may be associated with long term outcomes after treatment. 15 patients normally having pre-operative radiotherapy as part of their sarcoma treatment will be recruited to this study. Patients will have an additional three specialised MRI scans: one prior to the start of radiotherapy, one during the second week of radiotherapy while on treatment and one scan a week before surgery but after the completion of radiotherapy. Post-operatively, results of the histological examination of the sarcoma will be correlated to both the MRI scan data and outcomes after treatment

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Sarcoma

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
15 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MRI scanning
Arm Type
Experimental
Arm Description
patients undergo special MRI techniques (DWI-MRI and DCE-MRI) after their routine MRI examinations while undergoing routine radiotherapy. 3 lots of scans in total. They will also have a blood test.
Intervention Type
Device
Intervention Name(s)
MRI scanning
Primary Outcome Measure Information:
Title
Correlate histological response of soft tissue sarcoma after pre-operative radiotherapy with pre-treatment DWI and DCE-MRI parameters.
Description
The hypothesis is that quantitative biomarkers from DWI and DCE MRI can not only be produced with high spatial resolution in soft tissue sarcoma, but that these imaging biomarkers will correlate with histological and histochemical features of the tumour and will provide information to support the prediction of regional response to radiotherapy.
Time Frame
average of 9 weeks including radiotherapy up to one week before surgery
Secondary Outcome Measure Information:
Title
early response prediction of treatment using functional parameters of in-treatment imaging with DWI and DCE-MRI (e.g. relative change in apparent diffusion coefficient values)
Time Frame
following surgery at week 7
Title
accuracy of outlining treatment volumes using STIR. T1W, T2W and DWI MRI compared to standard planning CT and loco-regional control patterns
Time Frame
3 month follow up visit
Title
local recurrence patterns with pre-treatment functional MRI.
Description
Within our study, these patients would have an additional three specialised MRI scans: one prior to the start of radiotherapy, one during the second week of radiotherapy while on treatment and one scan the week before the operation after the completion of radiotherapy
Time Frame
3 timepoints for scans over 6 weeks of treatment

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients must have histologically confirmed diagnosis of intermediate/high grade soft tissue sarcoma (STS) Patients must be suitable for treatment with preoperative radiotherapy and radical surgery Standard radiological assessments (CT or MRI) may have already been performed but must be done within 4 weeks of starting radiotherapy Patient must have measurable disease on CT/MRI imaging ECOG performance status 0-2 Adequate pre-treatment haematological and biochemical parameters Age greater than or equal to 18 years No significant co-morbidity thereby excluding patient from having radical treatment. No previous treatment for diagnosis of STS including neo-adjuvant chemotherapy Women of child bearing age MUST have a negative pregnancy test prior to study entry and be using an adequate contraception method unless child bearing potential has been terminated by surgery/radical radiotherapy Patients must have given written informed consent Exclusion Criteria: Patients with cardiac pacemakers, cochlear implants, intraocular foreign bodies or any other MRI incompatibility factors (e.g. recent surgery). Patients with a known history of anaphylactic reaction to contrast material for MRI Previous administration of gadoxetic acid or other contrast material 24hr prior to or after the MRI Any evidence of severe or uncontrolled systemic diseases which, in the view of the investigator, makes it undesirable for the patient to participate in the trial Evidence of significant clinical disorder or laboratory finding which, in the opinion of the investigator makes it undesirable for the patient to participate in the trial Any other serious uncontrolled medical conditions Clinical evidence of metastatic disease Any pregnant or lactating woman Any patient with a medical or psychiatric condition that impairs their ability to give informed consent Evidence of impaired renal function, serum creatinine >1.5x upper limit of normal
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Prakash Manoharan
Organizational Affiliation
The Christie NHS Foundation Trust
Official's Role
Study Chair
Facility Information:
Facility Name
The Christie NHS Foundation Trust
City
Manchester
ZIP/Postal Code
M20 4BX
Country
United Kingdom

12. IPD Sharing Statement

Learn more about this trial

MRI in Pre-operative Radiotherapy for Soft Tissue Sarcoma: MISTS Study

We'll reach out to this number within 24 hrs